多発性骨髄腫における単剤療法およびデキサメタゾンおよびカルフィルゾミブとのさまざまな組み合わせにおける BGB-11417 の第 1b/2 相試験
再発/難治性多発性骨髄腫および t(11;14) 患者におけるデキサメタゾンおよびカーフィルゾミブ/デキサメタゾンとの併用による、単剤療法としての BGB-11417 の安全性と有効性を判断するための第 1b/2 相用量漸増およびコホート拡大研究
The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM) and chromosomal translocation t(11;14).
The study investigates sonrotoclax alone and in combination with dexamethasone and other agents, including carfilzomib, daratumumab, and pomalidomide.
調査の概要
状態
条件
詳細な説明
Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:BeOne Medicines
- 電話番号:1.877.828.5568
- メール:clinicaltrials@beonemed.com
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35294-0004
- 募集
- University of Alabama At Birmingham Hospital
-
-
California
-
Duarte、California、アメリカ、91010-3012
- 募集
- City of Hope National Medical Center
-
Irvine、California、アメリカ、92618-2377
- 募集
- City of Hope Irvine Lennar
-
-
Florida
-
Miami、Florida、アメリカ、33136-2107
- 募集
- University of Miami
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30322-1013
- 募集
- Emory University Winship Cancer Center
-
-
Illinois
-
Chicago、Illinois、アメリカ、60637-1443
- 募集
- University of Chicago Medical Center
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02114
- 完了
- Massachusetts General Hospital
-
-
Missouri
-
St Louis、Missouri、アメリカ、63110-1010
- 募集
- Washington University School of Medicine
-
-
New Jersey
-
Hackensack、New Jersey、アメリカ、07601-1915
- 募集
- Hackensack University Medical Center
-
-
New York
-
New York、New York、アメリカ、10065-6800
- 募集
- Memorial Sloan Kettering Cancer Center Mskcc
-
-
Ohio
-
Columbus、Ohio、アメリカ、43210-1240
- 募集
- The James Cancer Hospital and Solove Research Institute At Ohio State University
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84112-5550
- 募集
- Huntsman Cancer Institute
-
-
Washington
-
Seattle、Washington、アメリカ、98195
- 募集
- University of Washington
-
-
Wisconsin
-
Madison、Wisconsin、アメリカ、53792-0001
- 募集
- University of Wisconsin Carbone Cancer Center
-
Milwaukee、Wisconsin、アメリカ、53226-3522
- 募集
- Medical College of Wisconsin
-
-
-
-
-
Headington、イギリス、OX3 7LE
- 募集
- Oxford University Hospitals Nhs Trust Churchill Hospital
-
London、イギリス、NW1 2PG
- 募集
- University College Hospital
-
Sutton、イギリス、SM2 5PT
- 募集
- Royal Marsden Nhs Foundation Royal Marsden Hospital
-
-
-
-
-
Ancona、イタリア、60020
- 募集
- Azienda Ospedaliera Universitaria Delle Marche
-
Bari、イタリア、70124
- 募集
- Azienda Ospedaliera Policlinico Di Bari
-
Bologna、イタリア、40138
- 募集
- Policlinico Sorsola Malpighi, Aou Di Bologna
-
Meldola、イタリア、47014
- 募集
- Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst
-
Milan、イタリア、20141
- 募集
- Istituto Europeo Di Oncologia
-
-
-
-
Australian Capital Territory
-
Garran、Australian Capital Territory、オーストラリア、ACT 2605
- 募集
- Canberra Hospital
-
-
New South Wales
-
Kingswood、New South Wales、オーストラリア、NSW 2747
- 募集
- Nepean Hospital
-
-
Victoria
-
Clayton、Victoria、オーストラリア、VIC 3168
- 募集
- Monash Health
-
Fitzroy、Victoria、オーストラリア、VIC 3065
- 募集
- St Vincents Hospital Melbourne
-
Melbourne、Victoria、オーストラリア、VIC 3004
- 募集
- The Alfred Hospital
-
-
Western Australia
-
Perth、Western Australia、オーストラリア、WA 6000
- 募集
- Royal Perth Hospital
-
-
-
-
Alberta
-
Edmonton、Alberta、カナダ、T6G 1Z2
- 募集
- Cross Cancer Institute
-
-
British Columbia
-
Vancouver、British Columbia、カナダ、V5Z 4E6
- 募集
- British Columbia Cancer Agency the Vancouver Centre
-
-
Ontario
-
Toronto、Ontario、カナダ、M5G 2M9
- 募集
- Princess Margaret Cancer Centre
-
-
-
-
-
Alexandroupoli、ギリシャ、68100
- 募集
- University Hospital of Alexandroupolis
-
Athens、ギリシャ、115 28
- 募集
- General Hospital of Athens Alexandra
-
-
-
-
-
Singapore、シンガポール、119074
- 募集
- National University Hospital Singapore
-
-
-
-
-
Barcelona、スペイン、08036
- 積極的、募集していない
- Hospital Clinic de Barcelona
-
-
-
-
-
Aachen、ドイツ、52074
- 募集
- Universitaetsklinikum Aachen
-
Dresden、ドイツ、01307
- 募集
- Universitatsklinikum Carl Gustav Carus An Der Technischen Universitat Dresden
-
Hamburg、ドイツ、20251
- 募集
- Universitatsklinikum Hamburg Eppendorf
-
Würzburg、ドイツ、97080
- 募集
- Universitatsklinikum Wurzburg
-
-
-
-
-
Poitiers、フランス、86000
- 完了
- Chu de Poitiers Site de La Mileterie
-
-
-
-
-
Brasília、ブラジル、70200-730
- 募集
- Hospital Sirio Libanes Brasilia
-
Brasília、ブラジル、70390140
- 募集
- Instituto Dor de Pesquisa E Ensino Distrito Federal
-
Porto Alegre、ブラジル、90110-270
- 募集
- Centro Gaucho Integrado de Oncologia Hospital Mae de Deus
-
Salvador、ブラジル、41253-190
- 募集
- Hospital Sao Rafael (Rede Dor)
-
São Paulo、ブラジル、05652-900
- 募集
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
-
São Paulo、ブラジル、01401-004
- 募集
- Instituto Dor de Pesquisa E Ensino Sao Paulo
-
São Paulo、ブラジル、01308-050
- 募集
- Hospital Sirio Libanes
-
-
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100044
- 募集
- Peking University Peoples Hospital
-
Beijing、Beijing Municipality、中国、100000
- 募集
- Peking University Third Hospital
-
Beijing、Beijing Municipality、中国、100020
- 募集
- Beijing Chao Yang Hospital
-
-
Chongqing Municipality
-
Chongqing、Chongqing Municipality、中国、400030
- 募集
- Chongqing Cancer Hospital
-
-
Fujian
-
Fuzhou、Fujian、中国、350001
- 完了
- Fujian Medical University Union Hospital
-
Xiamen、Fujian、中国、361003
- 完了
- The First Affiliated Hospital of Xiamen University
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510060
- 募集
- Sun Yat Sen University Cancer Center
-
-
Hebei
-
Shijiazhuang、Hebei、中国、050000
- 完了
- The Second Hospital of Hebei Medical University
-
-
Henan
-
Zhengzhou、Henan、中国、450000
- 募集
- Henan Cancer Hospital
-
Zhengzhou、Henan、中国、450052
- 積極的、募集していない
- The First Affiliated Hospital of Zhengzhou University
-
-
Hubei
-
Wuhan、Hubei、中国、430022
- 募集
- Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
-
-
Hunan
-
Changsha、Hunan、中国、410013
- 完了
- Hunan Cancer Hospital
-
-
Jiangsu
-
Nanjing、Jiangsu、中国、210029
- 募集
- Jiangsu Province Hospital
-
-
Jiangxi
-
Nanchang、Jiangxi、中国、332000
- 募集
- The First Affiliated Hospital of Nanchang University Branch Xianghu
-
-
Liaoning
-
Shenyang、Liaoning、中国、110001
- 募集
- The First Hospital of China Medical University
-
-
Shandong
-
Qingdao、Shandong、中国、266000
- 募集
- Qingdao Municipal Hospital
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200032
- 募集
- Affiliated Zhongshan Hospital of Fudan University
-
Shanghai、Shanghai Municipality、中国、200434
- 完了
- Shanghai Fourth Peoples Hospital Affiliated to Tongji University
-
-
Tianjin Municipality
-
Tianjin、Tianjin Municipality、中国、301617
- 募集
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciencestuanbo Branch
-
Tianjin、Tianjin Municipality、中国、300052
- 完了
- Tianjin Medical University General Hospital
-
-
Zhejiang
-
Hangzhou、Zhejiang、中国、310003
- 募集
- The First Affiliated Hospital, Zhejiang University School of Medicine
-
-
-
-
Seoul Teugbyeolsi
-
GangnamGu、Seoul Teugbyeolsi、韓国、06351
- 募集
- Samsung Medical Center
-
SeochoGu、Seoul Teugbyeolsi、韓国、06591
- 募集
- The Catholic University of Korea, Seoul St Marys Hospital
-
SeodaemunGu、Seoul Teugbyeolsi、韓国、03722
- 募集
- Severance Hospital Yonsei University Health System
-
Seoul、Seoul Teugbyeolsi、韓国、03080
- 募集
- Seoul National University Hospital
-
SongpaGu、Seoul Teugbyeolsi、韓国、05505
- 募集
- Asan Medical Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
-
A confirmed diagnosis of multiple myeloma (must have an M-component in serum and/or urine)
-
Measurable disease defined as:
i. M-spike ≥ 500mg/dL, or ii. Urine protein M-spike of ≥ 200 mg/day, or iii. Serum free light chains ≥ 10 mg/dL, and an abnormal κ:λ ratio
-
Participant has documented relapsed or progressive MM on or after any regimen or who are refractory to the most recent line of therapy.
i. Relapsed MM is defined as previously treated MM that progresses and requires initiation of salvage therapy but does not meet the criteria for refractory MM.
ii. Refractory MM is defined as disease that is nonresponsive (failure to achieve minimal response or development of progressive disease) while on primary or salvage therapy or progresses within 60 days of last therapy.
- In Part 1 and Part 2 Cohorts 1 and 2 participants should have relapsed or progressive disease and have had ≥ 3 prior lines of therapy including a proteasome inhibitor, an IMiD, and an anti-CD38 monoclonal antibody, and no more available approved therapies.
- Participants in Part 2 Cohorts 3, 4, and 5 should have relapsed or progressive disease and have had ≥ 1 prior line of therapy. Prior treatment with carfilzomib is allowed but the patient must not be considered carfilzomib refractory by the investigator.
- Participants in Part 2 Cohorts 6 and 7 should have relapsed or progressive disease and have had 1 to 3 prior lines of therapy and previously treated with a proteasome inhibitor and an IMiD
-
Positivity for t(11;14) translocation must be confirmed by validated fluorescence in situ hybridization (FISH) testing assay in a pre-defined laboratory
a. fresh bone marrow aspirate sample must be collected at screening and sent to central laboratory for t(11;14) FISH testing.
-
Adequate organ function defined as:
- Hemoglobin ≥ 8.0 g/dL within 7 days before first dose of study treatment, (transfusions, in accordance with institutional guidelines, are permitted)
- Platelet count ≥ 75,000/μL, within 7 days before first dose of study treatment, independent of growth factor support and transfusions
- Absolute neutrophil count (ANC) ≥ 1000/mm^3 within 7 days before first dose of study treatment
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x upper limit of normal (ULN) and total bilirubin ≤ 2.0 x ULN N (total bilirubin must be < 3 x ULN for patients with Gilbert's syndrome)
Exclusion Criteria:
-
Participant has any of the following conditions:
- Non secretory MM (Serum free light chains < 10 mg/dL)
- Solitary plasmacytoma
- Active plasma cell leukemia (ie, either 20% of peripheral white blood cells or > 2.0 x 109/L circulating plasma cells by standard differential)
- Waldenström macroglobulinemia (WM)
- Amyloidosis.
- Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes (POEMS) syndrome
- Chronic respiratory disease that requires continuous oxygen
-
Significant cardiovascular disease, including but not limited to:
- Myocardial infarction ≤ 6 months before screening
- Ejection fraction ≤ 50%
- Unstable angina≤ 3 months before screening
- New York Heart Association Class III or IV congestive heart failure
- History of clinically significant arrhythmias (eg, sustained ventricular tachycardia, ventricular fibrillation, or torsades de pointes)
- Heart rate-corrected QT interval > 480 milliseconds based on Fridericia's formula
- History of Mobitz II second-degree or third-degree heart block without a permanent pacemaker in place
- Uncontrolled hypertension at screening, defined as systolic blood pressure > 170 mmHg and diastolic blood pressure > 105 mmHg by ≥ 2 consecutive measurements. Prior therapy with sonrotoclax or other agents inhibiting BCL2 activity (eg, venetoclax)
-
Known infection with human immunodeficiency virus (HIV)
-
Serologic status reflecting active viral hepatitis B (HBV) or viral hepatitis C (HCV) infection as follows:
- Presence of hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb). Participants with presence of HBcAb, but absence of HBsAg, are eligible if HBV DNA is undetectable (limitation of sensitivity < 20 IU/mL) ,), and if they are willing to undergo monthly monitoring for HBV reactivation.
- Presence of HCV antibody. Participants with presence of HCV antibody are eligible if HCV RNA is undetectable (limitation of sensitivity < 15 IU/mL).
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Part 1 Dose Escalation
Dose-escalation and de-escalation to determine maximum tolerated dose (MTD) of sonrotoclax plus dexamethasone, sonrotoclax plus dexamethasone plus carfilzomib, sonrotoclax plus dexamethasone plus daratumumab, and sonrotoclax plus dexamethasone plus pomalidomide. |
Administered orally daily
他の名前:
Once weekly either orally or intravenously Administered intravenously weekly Administered subcutaneously weekly Administered orally daily |
|
実験的:Part 2 Cohort Expansion
There will be up to 7 expansion cohorts to further evaluate the safety and efficacy of sonrotoclax monotherapy, sonrotoclax plus dexamethasone in combination with dexamethasone plus carfilzomib, and in combination with dexamethasone plus daratumumab |
Administered orally daily
他の名前:
Once weekly either orally or intravenously Administered intravenously weekly |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
パート1および2:1つまたは複数の治療に浸透した有害事象(TEAE)、深刻な有害事象(SAE)、中止および特別な関心のある有害事象(AESIS)につながる有害事象を報告する参加者の数。
時間枠:最後の研究薬の最大30日後
|
最後の研究薬の最大30日後
|
|
|
Part 1: Number Of Participants Experiencing Dose-limiting Toxicities (DLTs)
時間枠:Up to 28 days
|
DLTs will be based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 and will include most grade 3 or higher events, as defined in the protocol. |
Up to 28 days
|
|
Part 2: Overall response rate (ORR) as Assessed by Investigator
時間枠:Approximately 4 years
|
Defined as the percentage of participants who achieved a stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) per International Myeloma Working Group (IMWG) criteria |
Approximately 4 years
|
|
Part 2: Very Good Partial Response (VGPR) or Better Response Rate as Assessed by Investigator
時間枠:Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years]
|
Defined as the percentage of participants with a documented VGPR or better (including sCR, CR, and VGPR) |
Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years]
|
|
Part 2: Complete Response (CR) or Stringent Complete Response (sCR) as Assessed by Investigator
時間枠:Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years])
|
defined as the percentage of participants with a documented CR or sCR |
Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years])
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
パート1:sonrotoclaxの単回投与後のプラズマ濃度時間曲線時刻0から最後の測定可能濃度(オークラスト)までの面積
時間枠:サイクル1(各サイクルは最大28日です)
|
サイクル1(各サイクルは最大28日です)
|
|
|
パート1:sonrotoclaxの単回投与後の最大観測血漿濃度(CMAX)
時間枠:サイクル1(各サイクルは最大28日です)
|
サイクル1(各サイクルは最大28日です)
|
|
|
パート1:Sonrotoclaxの単回投与後にCMAX(TMAX)に到達する時間
時間枠:サイクル1(各サイクルは最大28日です)
|
サイクル1(各サイクルは最大28日です)
|
|
|
パート1:定常状態で:auc last、ss
時間枠:サイクル2(各サイクルは最大28日です)
|
サイクル2(各サイクルは最大28日です)
|
|
|
パート1:定常状態で:CMAX、SS
時間枠:サイクル2(各サイクルは最大28日です)
|
サイクル2(各サイクルは最大28日です)
|
|
|
パート1:定常状態で:トラフプラズマ濃度(Ctrough)SS
時間枠:サイクル2(各サイクルは最大28日です)
|
サイクル2(各サイクルは最大28日です)
|
|
|
パート1:定常状態で:CMAXに到達する時間(TMAX、SS)
時間枠:サイクル2(各サイクルは最大28日です)
|
サイクル2(各サイクルは最大28日です)
|
|
|
Part 2: Time to response (TTR) as Assessed by Investigator
時間枠:Approximately 4 years
|
TTR is defined as the time from start of treatment (for nonrandomized cohorts) or date of randomization (for randomized cohorts to first documentation of response of Partial Response (PR) or better |
Approximately 4 years
|
|
Part 2: Duration of response (DOR) as Assessed by Investigator
時間枠:Approximately 4 years
|
DOR is defined as the time from the date of the first documented response (PR or better) after treatment initiation until the date of first documented disease progression or death due to any cause, whichever occurs first. DOR will be analyzed only for patients who have achieved an overall response of at least PR. The distribution of DOR will be summarized by the Kaplan-Meier method. |
Approximately 4 years
|
|
Part 2: Progression-free survival (PFS) as Assessed by Investigator
時間枠:Approximately 4 years
|
PFS is defined as time from start of treatment (for nonrandomized cohorts) or date of randomization (for randomized cohorts) to the first documentation of disease progression or death, whichever occurs first |
Approximately 4 years
|
|
Part 2: Overall survival (OS) as Assessed by Investigator
時間枠:Approximately 4 years
|
OS defined as the time from start of treatment (for nonrandomized cohorts) or date of randomization (for randomized cohorts to the date of death due to any cause |
Approximately 4 years
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- BGB-11417-105
- 2021-003614-39 (EudraCT番号)
- U1111-1277-5444 (その他の識別子:UTN Number)
- 2023-507751-30-00 (Ctis)
- CTR20231932 (その他の識別子:ChinaDrugTrials)
- 2023 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.
BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.
Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
IPD 共有時間枠
See plan description
IPD 共有アクセス基準
See plan description
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。